重组型组织纤溶酶原激活剂联合他汀扩大时间窗溶栓治疗急性脑梗死研究

被引：11

作者：

王少君 ^{[1
]}

刘建 ^{[1
]}

马海 ^{[1
]}

刘连峰 ^{[1
]}

霍金莲 ^{[1
]}

刘永宏 ^{[1
]}

彭国光 ^{[2
]}

机构：

[1] 延安大学咸阳医院神经内科

[2] 重庆医科大学附属第一医院神经内科

来源：

中华临床医师杂志(电子版) | 2014年 / 8卷 / 12期

关键词：

脑梗死; 阿托伐他汀; 神经保护作用; rt-PA溶栓;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

1002 ;

摘要：

目的探讨阿托伐他汀联合重组型组织纤溶酶原激活剂(rt-PA)治疗发病4.5～6 h急性脑梗死的安全性和有效性。方法发病4.5～6 h内急性脑梗死患者42例,随机分为对照组和试验组。试验组入院后即予阿托伐他汀联合rt-PA治疗(剂量为0.6 mg/kg,最大剂量不超过90 mg);溶栓治疗后24 h如无出血等并发症发生,可予阿司匹林和阿托伐他汀治疗;对照组入院后常规予阿司匹林和阿托伐他汀治疗;同时予控制血压和血糖、对症治疗等药物治疗。随访两组90 d主要终点指标是症状性脑出血发生率;次要终点指标是治疗后24 h神经功能改善情况和发病3个月临床预后[改良Rankin量表(mRS)评分]。结果症状性脑出血2例,试验组1例,对照组1例,均出现在大面积脑梗死患者,无一例死亡病例。试验组早期神经功能改善较对照组高(47.6%vs.33.3%),差异有统计学意义(P<0.05);试验组临床预后良好(mRS<2)者较对照组增加(47.6%vs.38.1%),有好转趋势,但差异无统计学意义(P>0.05)。结论发病4.5～6 h内他汀联合rt-PA治疗是安全的,并可改善急性脑梗死早期神经功能。

引用

页码：2246 / 2249

页数：4

共 9 条

[1]

Combining Statins with Tissue Plasminogen Activator Treatment After Experimental and Human Stroke: A Safety Study on Hemorrhagic Transformation[J] . Mireia Campos,Lidia García‐Bonilla,Mar Hernández‐Guillamon,Verónica Barceló,Anna Morancho,Manolo Quintana,Marta Rubiera,Anna Rosell,Joan Montaner.CNS Neurosci Ther . 2013 (11)

[2] Challenges in Acute Ischemic Stroke Clinical Trials [J].

Furlan, Anthony J. .

CURRENT CARDIOLOGY REPORTS, 2012, 14 (06) :761-766

[3]

Neuroprotective Effects of Statins: Evidence from Preclinical and Clinical Studies[J] . Marc Fisher,Majaz Moonis.Current Treatment Options in Cardiovascular Medicine . 2012 (3)

[4] Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival [J].

Flint, Alexander C. ;

Kamel, Hooman ;

Navi, Babak B. ;

Rao, Vivek A. ;

Faigeles, Bonnie S. ;

Conell, Carol ;

Klingman, Jeff G. ;

Sidney, Stephen ;

Hills, Nancy K. ;

Sorel, Michael ;

Cullen, Sean P. ;

Johnston, S. Claiborne .

STROKE, 2012, 43 (01) :147-154

[5]

Statin Treatment and Functional Outcome After Ischemic Stroke: Case–Control and Meta-Analysis[J] . Alessandro Biffi,William J. Devan,Christopher D. Anderson,Lynelle Cortellini,Karen L. Furie,Jonathan Rosand,Natalia S. Rost.Stroke A Journal of Cerebral Circulation . 2011 (5)

[6]

Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study[J] . Danielle Ní Chróinín,Elizabeth L. Callaly,Joseph Duggan,áine Merwick,Niamh Hannon,órla Sheehan,Michael Marnane,Gillian Horgan,Emma B. Williams,Dawn Harris,Lorraine Kyne,Patricia M.E. McCormack,Joan Moroney,Tim Grant,David Williams,Leslie Daly,Peter J. Kelly.Stroke . 2011 (4)

[7]

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT （DIAS-2）: a prospective, randomised, double-blind, placebo-controlled study[J] . Lancet Neurology . 2009 (2)

[8]

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits[J] . Paul A. Lapchak,Moon Ku Han.Brain Research . 2009

[9] Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat [J].

Zhang, L ;

Zhang, ZG ;

Ding, GL ;

Jiang, Q ;

Liu, XS ;

Meng, H ;

Hozeska, A ;

Zhang, CL ;

Li, L ;

Morris, D ;

Zhang, RL ;

Lu, M ;

Chopp, M .

CIRCULATION, 2005, 112 (22) :3486-3494

← 1 →